Gonadotropin-releasing hormone agonist versus expectant management for treating multiple leiomyomas after myomectomy: the study protocol for a multicentre, prospective, randomised controlled clinical trial
Guardado en:
Autores principales: | Xin Du, Jia Wei, Li Hong, Shixuan Wang, Ruixia Guo, Minli Zhang, Xiangyi Ma, Wenwen Wang, Zhiying Yu, Zhiying Li, Yun Feng, Chunlian Zhang, Qingfen Yue, Wuliang Wang |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/741e2206a03f4d9495b918942085b0d9 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
A prognostic index model for predicting long-term recurrence of uterine leiomyoma after myomectomy.
por: Xiu Ming, et al.
Publicado: (2021) -
Increased risk of pneumonia in patients receiving gonadotropin-releasing hormone agonists for prostate cancer.
por: Shiu-Dong Chung, et al.
Publicado: (2014) -
Response to the gonadotropin releasing hormone agonist leuprolide in immature female sheep androgenized in utero
por: RECABARREN,SERGIO E, et al.
Publicado: (2005) -
ROLE OF ULTRASOUND IN THE SELECTION OF ACCESS FOR MYOMECTOMY
por: Сергей Валерьевич Рыбников, et al.
Publicado: (2021) -
Effects of artificial cycles with and without gonadotropin-releasing hormone agonist pretreatment on frozen embryo transfer outcomes in patients with adenomyosis
por: Muzi Li, et al.
Publicado: (2021)